Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

Levin, V A

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Oct 2000 - 3878-84 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.

1078-0432


Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Brain Neoplasms--drug therapy
Cisplatin--administration & dosage
Cyclophosphamide--administration & dosage
Disease-Free Survival
Dose-Response Relationship, Drug
Eflornithine--administration & dosage
Female
Glioblastoma--drug therapy
Humans
Lomustine--administration & dosage
Male
Middle Aged
Procarbazine--administration & dosage
Prospective Studies
Time Factors
Vincristine--administration & dosage
Vindesine--administration & dosage